{"id":21940,"date":"2023-02-20T23:03:00","date_gmt":"2023-02-20T15:03:00","guid":{"rendered":"https:\/\/flcube.com\/?p=21940"},"modified":"2025-01-18T23:19:21","modified_gmt":"2025-01-18T15:19:21","slug":"zhejiang-suspends-generic-nesina-trading-due-to-ip-disputes","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=21940","title":{"rendered":"Zhejiang Suspends Generic Nesina Trading Due to IP Disputes"},"content":{"rendered":"\n

Zhejiang’s Provincial Center for Drug & Medical Device Procurement has issued a notification suspending the online trading qualifications for generic versions of Takeda’s (TYO: 4502<\/a>) Nesina (alogliptin). The notice specifically targets products manufactured by Jiangsu Zhongtian Pharmaceutical Co., Ltd and Sinopharm Guorui Pharmaceutical Co. Ltd. This suspension is part of recent policies aimed at ensuring that intellectual property (IP) rights protections and ongoing disputes are reflected during centralized drug procurement. Products currently involved in legal disputes are to be barred from provincial tenders.<\/p>\n\n\n\n

Background on Nesina<\/strong>
Nesina is a dipeptidyl peptidase-4 (DPP-4) inhibitor used to treat type 2 diabetes. It was first approved in Japan in 2010 and introduced to China in 2013. Takeda filed for an invention patent in China for the drug (Patent Three) in September 2006, based on which another four patents were filed, including Patent One and Patent Two. All five patents were authorized, with a validation period lasting until September 13, 2026.<\/p>\n\n\n\n

Patent Challenges and Outcomes<\/strong>
Yabao Pharma challenged Patent One (No. ZL201210332271.8), Patent Two (No. ZL201210399309.3), and Patent Three (No. ZL200680042417.8), all named \u201cDipeptidyl peptidase inhibitors for the treatment of diabetes.\u201d The challenges were respectively for the protection of the pharmaceutical composition containing alogliptin and carrier (Patent One), the pharmaceutical use of alogliptin for the preparation of treatment of type 2 diabetes (Patent Two), and the pharmaceutical composition of alogliptin in the form of a single dose of a specific specification (Patent Three). The outcomes were that Patent One was declared partially invalid (while keeping the technical scheme of combined medication), Patent Two was declared invalid overall, and Patent Three was confirmed to enjoy priority rights (remaining valid). Yabao Pharma\u2019s product eventually became the generic of Nesina to be marketed in China in November 2019.<\/p>\n\n\n\n

Market Landscape and Patent Declarations<\/strong>
Since then, Zhongtian Pharma and Sinopharm, among a total of eight companies, have had generic versions approved for marketing in China. Only Ideal Pharma and Xinhua Pharma have made patent declarations for the drug under China’s new patent linkage system. Both made Category 3 declarations, indicating that the generics applicants promise not to market the product before patent expiration.<\/p>\n\n\n\n

DPP-4 Inhibitors in China<\/strong>
Six DPP-4 inhibitors, including MSD\u2019s sitagliptin, BMS\/AZ\u2019s saxagliptin, Novartis\u2019s vildagliptin, BI\u2019s linagliptin, and Mitsubishi Tanabe’s teneligliptin, as well as alogliptin, are commercially available in China. Saxagliptin and vildagliptin were involved in the fifth and third volume-based procurement (VBP) rounds, and linagliptin was suspended for procurement due to an IP issue involving HEC.<\/p>\n\n\n\n

Note on Webpage Access<\/strong>
Due to network issues, the webpage (https:\/\/zldj.cde.org.cn) could not be successfully parsed. If the specific content of this webpage is crucial for your needs, it is recommended to check the validity of the link and try accessing it again. Alternatively, if you have any other questions or need further assistance with this topic, feel free to ask.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Zhejiang’s Provincial Center for Drug & Medical Device Procurement has issued a notification suspending the…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[11,4],"tags":[2346,39,31,73,3195,345,1141,3194],"class_list":["post-21940","post","type-post","status-publish","format-standard","hentry","category-drug","category-policy-regulatory","tag-centralized-procurement","tag-diabetes","tag-generic-drugs","tag-patents","tag-sinopharm-guorui-pharmaceutical","tag-takeda","tag-tyo-4502","tag-zhongtian-pharmaceutical"],"yoast_head":"\nZhejiang Suspends Generic Nesina Trading Due to IP Disputes - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Zhejiang's Provincial Center for Drug & Medical Device Procurement has issued a notification suspending the online trading qualifications for generic versions of Takeda's (TYO: 4502) Nesina (alogliptin). The notice specifically targets products manufactured by Jiangsu Zhongtian Pharmaceutical Co., Ltd and Sinopharm Guorui Pharmaceutical Co. Ltd. This suspension is part of recent policies aimed at ensuring that intellectual property (IP) rights protections and ongoing disputes are reflected during centralized drug procurement. Products currently involved in legal disputes are to be barred from provincial tenders.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=21940\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zhejiang Suspends Generic Nesina Trading Due to IP Disputes\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=21940\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-20T15:03:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-18T15:19:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21940#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21940\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Zhejiang Suspends Generic Nesina Trading Due to IP Disputes\",\"datePublished\":\"2023-02-20T15:03:00+00:00\",\"dateModified\":\"2025-01-18T15:19:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21940\"},\"wordCount\":489,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Centralized procurement\",\"Diabetes\",\"Generic drugs\",\"Patents\",\"Sinopharm Guorui Pharmaceutical\",\"Takeda\",\"TYO: 4502\",\"Zhongtian Pharmaceutical\"],\"articleSection\":[\"Drug\",\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21940#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21940\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=21940\",\"name\":\"Zhejiang Suspends Generic Nesina Trading Due to IP Disputes - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-02-20T15:03:00+00:00\",\"dateModified\":\"2025-01-18T15:19:21+00:00\",\"description\":\"Zhejiang's Provincial Center for Drug & Medical Device Procurement has issued a notification suspending the online trading qualifications for generic versions of Takeda's (TYO: 4502) Nesina (alogliptin). The notice specifically targets products manufactured by Jiangsu Zhongtian Pharmaceutical Co., Ltd and Sinopharm Guorui Pharmaceutical Co. Ltd. This suspension is part of recent policies aimed at ensuring that intellectual property (IP) rights protections and ongoing disputes are reflected during centralized drug procurement. Products currently involved in legal disputes are to be barred from provincial tenders.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21940#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21940\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21940#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zhejiang Suspends Generic Nesina Trading Due to IP Disputes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Zhejiang Suspends Generic Nesina Trading Due to IP Disputes - Insight, China's Pharmaceutical Industry","description":"Zhejiang's Provincial Center for Drug & Medical Device Procurement has issued a notification suspending the online trading qualifications for generic versions of Takeda's (TYO: 4502) Nesina (alogliptin). The notice specifically targets products manufactured by Jiangsu Zhongtian Pharmaceutical Co., Ltd and Sinopharm Guorui Pharmaceutical Co. Ltd. This suspension is part of recent policies aimed at ensuring that intellectual property (IP) rights protections and ongoing disputes are reflected during centralized drug procurement. Products currently involved in legal disputes are to be barred from provincial tenders.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=21940","og_locale":"en_US","og_type":"article","og_title":"Zhejiang Suspends Generic Nesina Trading Due to IP Disputes","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=21940","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-02-20T15:03:00+00:00","article_modified_time":"2025-01-18T15:19:21+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=21940#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=21940"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Zhejiang Suspends Generic Nesina Trading Due to IP Disputes","datePublished":"2023-02-20T15:03:00+00:00","dateModified":"2025-01-18T15:19:21+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=21940"},"wordCount":489,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Centralized procurement","Diabetes","Generic drugs","Patents","Sinopharm Guorui Pharmaceutical","Takeda","TYO: 4502","Zhongtian Pharmaceutical"],"articleSection":["Drug","Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=21940#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=21940","url":"https:\/\/flcube.com\/?p=21940","name":"Zhejiang Suspends Generic Nesina Trading Due to IP Disputes - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-02-20T15:03:00+00:00","dateModified":"2025-01-18T15:19:21+00:00","description":"Zhejiang's Provincial Center for Drug & Medical Device Procurement has issued a notification suspending the online trading qualifications for generic versions of Takeda's (TYO: 4502) Nesina (alogliptin). The notice specifically targets products manufactured by Jiangsu Zhongtian Pharmaceutical Co., Ltd and Sinopharm Guorui Pharmaceutical Co. Ltd. This suspension is part of recent policies aimed at ensuring that intellectual property (IP) rights protections and ongoing disputes are reflected during centralized drug procurement. Products currently involved in legal disputes are to be barred from provincial tenders.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=21940#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=21940"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=21940#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Zhejiang Suspends Generic Nesina Trading Due to IP Disputes"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21940","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21940"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21940\/revisions"}],"predecessor-version":[{"id":21943,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21940\/revisions\/21943"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21940"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21940"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21940"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}